Melola Discovery

← Melola Discovery

Jurnal SINTA 1

Tocilizumab as a Treatment for ‘Cytokine Storm Syndrome’ in COVID-19: A Case Report

ACTA MEDICA INDONESIANA · Vol. 53 No. 2 (2021)

ISSN
2338-2732, 0125-9326
Terbit
2021-07-11
Penerbit
The Indonesian Society of Internal Medicine
Bahasa
eng

Abstrak

Coronavirus disease 19 (COVID-19) which is caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), has been a problem worldwide, particularly due to the high rate of transmission and wide range of clinical manifestations. Acute respiratory distress syndrome (ARDS) and multiorgan failure are the most common events observed in severe cases and can be fatal. Cytokine storm syndrome emerges as one of the possibilities for the development of ARDS and multiorgan failure in severe cases of COVID-19. This case report describes a case of a 53-year-old male patient who has been diagnosed with COVID-19. Further evaluation in this patient showed that there was a marked increase in IL-6 level in blood accompanied with hyperferritinemia, which was in accordance with the characteristic of cytokine storm syndrome. Patient was treated with tocilizumab, a monoclonal antibody and is an antagonist to IL-6 receptor. The binding between tocilizumab and IL-6 receptors effectively inhibit and manage cytokine storm syndrome. Although this case report reported the efficacy of tocilizumab in managing cytokine storm syndrome, tocilizumab has several adverse effects requiring close monitoring. Further clinical randomized control trial is required to evaluate the efficacy and safety of tocilizumab administration in participants with various clinical characteristics and greater number of subjects.

Kata kunci

Jaringan kolaborasi para penulis

40 penulis · 319 tautan kepenulisan bersama · menampilkan 40 yang paling banyak terhubung

Arahkan kursor atau ketuk sebuah nama untuk menyorot rekan penulisnya. Klik dua kali untuk membuka halaman penulis.

  • University of Indonesia
  • Afiliasi tidak diketahui
  • Organisasi berbeda
  • Organisasi sama
  • Afiliasi tidak diketahui
  • Garis lebih tebal = lebih banyak artikel bersama · lingkaran lebih besar = lebih banyak artikel
Tampilkan sebagai tabel
Rekan penulisOrganisasiArtikel bersama
Kuntjoro HarimurtiAfiliasi tidak diketahui15
Hamzah ShatriAfiliasi tidak diketahui14
Siti SetiatiAfiliasi tidak diketahui12
Murdani AbdullahAfiliasi tidak diketahui9
Achmad FauziAfiliasi tidak diketahui6
Sally Aman NasutionAfiliasi tidak diketahui6
Kaka RenaldiAfiliasi tidak diketahui5
Eka GinanjarAfiliasi tidak diketahui5
Rudi PutrantoAfiliasi tidak diketahui5
Em YunirUniversity of Indonesia5
Evy YunihastutiAfiliasi tidak diketahui5
Cleopas Martin RumendeAfiliasi tidak diketahui5
Imam SubektiAfiliasi tidak diketahui5
Simon SalimAfiliasi tidak diketahui4
Ikhwan RinaldiAfiliasi tidak diketahui4
Rudy HidayatAfiliasi tidak diketahui4
Aria KekalihAfiliasi tidak diketahui4
Dyah PurnamasariAfiliasi tidak diketahui4
Leonard NainggolanAfiliasi tidak diketahui4
Lugyanti SukrismanAfiliasi tidak diketahui4
Muchtaruddin MansyurAfiliasi tidak diketahui3
Muhammad YaminAfiliasi tidak diketahui3
Ari F SyamAfiliasi tidak diketahui3
Iris RengganisAfiliasi tidak diketahui3
Nury NusdwinuringtyasAfiliasi tidak diketahui3
Birry KarimAfiliasi tidak diketahui3

Afiliasi berasal dari OpenAlex; metadata OAI-PMH jurnal tidak memuatnya. Penulis tanpa ID OpenAlex dicocokkan berdasarkan nama, sehingga dua orang bisa tergabung atau satu orang bisa terpisah.

Sumber metadata: OAI-PMH (metadata jurnal) http://www.actamedindones.org/index.php/ijim/oai, pertama di-harvest 8 Nov 2026, terakhir terlihat 8 Nov 2026.
Metadata asli (oai_dc) 
<oai_dc:dc xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/  http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en-US">Tocilizumab as a Treatment for ‘Cytokine Storm Syndrome’ in COVID-19: A Case Report</dc:title>
	<dc:creator>Syam, Ari Fahrial</dc:creator>
	<dc:creator>Pitoyo, Ceva W</dc:creator>
	<dc:creator>Suhendro, Suhendro</dc:creator>
	<dc:creator>Zulkarnain, Benny</dc:creator>
	<dc:creator>Indrasari, Nuri D</dc:creator>
	<dc:creator>Aditianingsih, Dita</dc:creator>
	<dc:creator>Irawan, Cosphiadi</dc:creator>
	<dc:creator>Susilo, Adityo</dc:creator>
	<dc:creator>Rumende, Cleopas M</dc:creator>
	<dc:creator>Wijaya, Ika P</dc:creator>
	<dc:creator>Ibrahim, Fera</dc:creator>
	<dc:creator>Rasmin, Menaldi</dc:creator>
	<dc:creator>Alwi, Idrus</dc:creator>
	<dc:creator>Makmun, Dadang</dc:creator>
	<dc:subject xml:lang="en-US">COVID-19</dc:subject>
	<dc:subject xml:lang="en-US">SARS-CoV-2</dc:subject>
	<dc:subject xml:lang="en-US">acute respiratory distress syndrome (ARDS)</dc:subject>
	<dc:subject xml:lang="en-US">Tocilizumab</dc:subject>
	<dc:description xml:lang="en-US">Coronavirus disease 19 (COVID-19) which is caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), has been a problem worldwide, particularly due to the high rate of transmission and wide range of clinical manifestations. Acute respiratory distress syndrome (ARDS) and multiorgan failure are the most common events observed in severe cases and can be fatal. Cytokine storm syndrome emerges as one of the possibilities for the development of ARDS and multiorgan failure in severe cases of COVID-19. This case report describes a case of a 53-year-old male patient who has been diagnosed with COVID-19. Further evaluation in this patient showed that there was a marked increase in IL-6 level in blood accompanied with hyperferritinemia, which was in accordance with the characteristic of cytokine storm syndrome. Patient was treated with tocilizumab, a monoclonal antibody and is an antagonist to IL-6 receptor. The binding between tocilizumab and IL-6 receptors effectively inhibit and manage cytokine storm syndrome. Although this case report reported the efficacy of tocilizumab in managing cytokine storm syndrome, tocilizumab has several adverse effects requiring close monitoring. Further clinical randomized control trial is required to evaluate the efficacy and safety of tocilizumab administration in participants with various clinical characteristics and greater number of subjects. </dc:description>
	<dc:publisher xml:lang="en-US">The Indonesian Society of Internal Medicine</dc:publisher>
	<dc:date>2021-07-11</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>http://www.actamedindones.org/index.php/ijim/article/view/1825</dc:identifier>
	<dc:source xml:lang="en-US">Acta Medica Indonesiana; Vol. 53 No. 2 (2021): Acta Medica Indonesiana; 194</dc:source>
	<dc:source>2338-2732</dc:source>
	<dc:source>0125-9326</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>http://www.actamedindones.org/index.php/ijim/article/view/1825/pdf</dc:relation>
	<dc:rights xml:lang="en-US">Copyright (c) 2021 Ari Fahrial Syam, Ceva W Pitoyo, Suhendro Suhendro, Benny Zulkarnain, Nuri D Indrasari, Dita Aditianingsih, Cosphiadi Irawan, Adityo Susilo, Cleopas M Rumende, Ika P Wijaya, Fera Ibrahim, Menaldi Rasmin, Idrus Alwi, Dadang Makmun</dc:rights>
</oai_dc:dc>